The combination statistically significantly improved overall survival, reducing the risk of death by 21% compared with chemotherapy alone. The Food and Drug Administration (FDA) has approved ...

The overall response rate was significantly higher for Keytruda plus chemotherapy versus chemotherapy alone (52% versus 29%). The approval marks first indication for Keytruda in MPM in the US ...

The company (MRK) said the approval is the first for Keytruda to treat MPM in the U.S. and is in combination with pemetrexed and platinum chemotherapy. MPM is a rare and aggressive malignancy ...

Merck (NYSE: MRK), known as MSD outside of the United States and Canada, today announced long-term overall survival (OS) data ...

Keytruda plus chemo has been approved for unresectable advanced or metastatic malignant pleural mesothelioma based on findings from the KEYNOTE-483 trial. The Food and Drug Administration (FDA) ...

Merck’s (NYSE:MRK) anti-PD-1 therapy Keytruda as part of a combination regimen with Eisai’s (OTCPK:ESALF) (OTCPK:ESAIY) Lenvima has reduced the risk of disease progression or death by 34% in a ...

Merck (NYSE:MRK) announced Saturday that its ant-PD-1 therapy Keytruda (pembrolizumab) reached the main goal in a Phase 3 trial with chemoradiotherapy in patients with cervical cancer, cutting ...

(RTTNews) - Drug major Merck & Co., Inc. (MRK) announced Wednesday that the U.S. Food and Drug Administration has approved its anti-PD-1 therapy KEYTRUDA (pembrolizumab), in combination with ...

Patients with previously untreated, high-risk locally advanced cervical cancer experienced improved survival when treated with Keytruda plus chemoradiotherapy. Keytruda (pembrolizumab) plus ...

Merck & Co. Inc. said Wednesday the U.S. Food and Drug Administration has approved its blockbuster cancer drug Keytruda as a treatment for malignant plural mesothelioma, a rare cancer associated ...